Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Drug: BI 706321
Drug: ustekinumab
Drug: Placebo

First Posted Date: 2021-07-27

Last Posted Date: 2025-05-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT04978493

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Southern Star Research Institute, LLC, San Antonio, Texas, United States
🇺🇸
University of Utah Health Sciences Center, Salt Lake City, Utah, United States

and more 46 locations

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

Phase 1

Active, not recruiting

Conditions: Solid Tumors, KRAS Mutation

Interventions: Drug: BI 1823911
Drug: BI 1701963
Drug: Midazolam

First Posted Date: 2021-07-22

Last Posted Date: 2025-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT04973163

Locations: 🇬🇧
The Christie, Manchester, United Kingdom
🇧🇪
Brussels - HOSP Jules Bordet, Anderlecht/Brussels-Capital, Belgium
🇧🇪
Edegem - UNIV UZ Antwerpen, Edegem/Antwerpen, Belgium

and more 5 locations

A Study in Healthy Men to Test How BI 474121 is Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 474121

First Posted Date: 2021-07-16

Last Posted Date: 2024-03-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT04964453

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 1569912

First Posted Date: 2021-07-12

Last Posted Date: 2023-10-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT04958252

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1

Recruiting

Conditions: Neoplasms

Interventions: Drug: BI 765179
Drug: Ezabenlimab
Drug: Pembrolizumab

First Posted Date: 2021-07-12

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 160

Registration Number: NCT04958239

Locations: 🇲🇽
Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico
🇺🇸
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
University of Arizona, Tucson, Arizona, United States

and more 44 locations

A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: nintedanib 25 mg
Drug: nintedanib 100 mg

First Posted Date: 2021-06-24

Last Posted Date: 2023-07-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT04938453

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

Phase 1

Completed

Conditions: Depressive Disorder, Major

Interventions: Drug: BI 1569912
Drug: Placebo

First Posted Date: 2021-06-24

Last Posted Date: 2023-11-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 59

Registration Number: NCT04937829

Locations: 🇺🇸
Research Centers of America, Oakland Park, Florida, United States
🇺🇸
Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸
Optimus U Corporation, Miami, Florida, United States

and more 6 locations

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Empagliflozin

First Posted Date: 2021-06-24

Last Posted Date: 2024-02-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16746

Registration Number: NCT04937816

Locations: 🇩🇪
Boehringer Ingelheim, Ingelheim am Rhein, Germany

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Empagliflozin

First Posted Date: 2021-06-16

Last Posted Date: 2021-07-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 460558

Registration Number: NCT04927858

Locations: 🇸🇪
Boehringer Ingelheim AB, Stockholm, Sweden

A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2021-06-15

Last Posted Date: 2022-12-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 39

Registration Number: NCT04926246

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy